Advertisement

Search Results

Advertisement



Your search for Ruben A. Mesa, MD matches 21 pages

Showing 1 - 21


AACI Members Choose Robert Winn, MD, as Vice President/President-Elect, and Other New Leaders

Robert Winn, MD, Director of Virginia Commonwealth University (VCU) Massey Cancer Center, has been elected by the members of the Association of American Cancer Institutes (AACI) to serve as Vice President/President-Elect of AACI’s Board of Directors. Dr. Winn’s new position is effective...

covid-19

Majority of Patients With Cancer Achieve Immune Response After COVID-19 Vaccination

In a U.S. and Swiss study, nearly all patients with cancer developed an immune response to COVID-19 mRNA vaccines 3 to 4 weeks after receiving their second dose. However, a small group of the patients exhibited no response, raising questions about how their protection against the virus will be...

hematologic malignancies

Novel Targeted Agents for the Treatment of Myelofibrosis

“Progress lies not in enhancing what is, but in advancing toward what will be.”                                                              –Kahlil Gibran To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting &...

hematologic malignancies

Ruben A. Mesa, MD, on Myelofibrosis, Transfusion Independence, and Momelotinib

Ruben A. Mesa, MD, of UT Health San Antonio Cancer Center, discusses new findings on momelotinib, a potent JAK1, JAK2, and ACVR1 inhibitor with clinical activity against hallmark features of myelofibrosis such as anemia and splenomegaly. Results showed that transfusion independence was associated...

hematologic malignancies

Selected ASH Abstracts on Novel Treatments of Polycythemia Vera

To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...

Breast Cancer and Radiation Researcher David Gius, MD, PhD, Joins Mays Cancer Center

David Gius, MD, PhD, a breast cancer and radiation researcher, has joined the Mays Cancer Center, home to The University of Texas Health San Antonio MD Anderson. He was recruited to the Mays Cancer Center from the Robert H. Lurie Comprehensive Cancer Center at Northwestern University with a $6...

hematologic malignancies

Fedratinib: Back From ­Development Limbo for the Treatment of ­Myeloproliferative Neoplasms

In September 2019, Dr. Claire Harrison and colleagues, myself among them, presented two new analyses regarding the use of the JAK2 and FLT3 inhibitor fedratinib in myelofibrosis at the Society of Hematologic Oncology (SOHO) Annual Meeting, with resulting publication in Clinical Lymphoma, Myeloma...

hematologic malignancies

Study Findings on Myeloproliferative Neoplasms Including Systemic Mastocytosis

HERE IS AN UPDATE on six different studies featured at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition. Topics focused on novel treatments for myelofibrosis, polycythemia vera and essential thrombocythemia, as well as systemic mastocytosis. Myelofibrosis ABSTRACT...

hematologic malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms: Managing PV and ET

Ruben A. Mesa, MD, of The University of Texas Health San Antonio Cancer Center, discusses the role of JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia and how to develop individualized therapy based on risk stratification.

hematologic malignancies

Momelotinib vs Ruxolitinib in Janus Kinase Inhibitor–Naive Myelofibrosis

In the phase III SIMPLIFY-1 noninferiority trial reported in the Journal of Clinical Oncology, Mesa et al found that the selective Janus kinase (JAK) 1 and 2 inhibitor momelotinib was noninferior to ruxolitinib (Jakafi) in spleen response, but not symptom response, in JAK inhibitor–naive...

hematologic malignancies
symptom management
supportive care
head and neck cancer
pancreatic cancer
solid tumors

NCCN Panelists Relay ‘What’s Hot’ in Their Fields

AT THE NATIONAL Comprehensive Cancer Network® (NCCN®) 22nd Annual Conference, experts from several fields met with journalists to highlight “what’s hot” in their specialties. The ASCO Post captured that conversation.  Myeloproliferative Neoplasms Guidelines  NCCN HAS LAUNCHED new NCCN Clinical...

hematologic malignancies

David H. Henry, MD, and Ruben A. Mesa, MD, on Myelofibrosis: Trial Results From a Best of ASCO Abstract

David H. Henry, MD, of Pennsylvania Oncology Hematology Associates, and Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discuss phase III study findings on momelotinib vs ruxolitinib in JAK inhibitor–naive patients with myelofibrosis. (Abstract 7000)

hematologic malignancies
breast cancer
lung cancer
kidney cancer
sarcoma
bladder cancer
colorectal cancer
multiple myeloma
genomics/genetics

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...

hematologic malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms and Myelofibrosis: New Treatment Guidelines 126

Ruben A. Mesa, MD, of the Mayo Clinic Cancer Center, discusses molecular abnormalities and their use in the diagnosis, risk stratification, and selection of treatment for myelofibrosis.

hematologic malignancies

NCCN Issues New Clinical Practice Guidelines for Myeloproliferative Neoplasms

Myeloproliferative neoplasms are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—myelofibrosis, essential thrombocythemia, and polycythemia vera—affect approximately 13,000; 134,000; and 148,000 patients in the...

hematologic malignancies

NCCN Publishes New Clinical Practice Guidelines for Myeloproliferative Neoplasms

Myeloproliferative neoplasms are a group of blood cancers characterized by significant symptoms and a high risk of transformation into acute leukemia. These cancers—myelofibrosis, essential thrombocythemia, and polycythemia vera—affect approximately 13,000, 134,000, and 148,000 patients ...

hematologic malignancies

Ruben A. Mesa, MD, and James O. Armitage, MD, Results of the PERSIST-1 Study on Myelofibrosis

James O. Armitage, MD, of The University of Nebraska Medical Center, and Ruben A. Mesa, MD, of the Mayo Clinic, discuss pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

hematologic malignancies

Ruben A. Mesa, MD, Summarizes Results of the PERSIST-1 Study on Myelofibrosis

Ruben A. Mesa, MD, of the Mayo Clinic, discusses pacritinib and its significant efficacy in myelofibrosis (Abstract LBA7006).

Updates on Ruxolitinib from ASCO and ASH 2012, including Long-term Survival Data

Ruxolitinib (Jakafi), a novel, oral JAK1 and JAK2 inhibitor, was approved by the FDA on November 16, 2011 for patients with intermediate- or high-risk myelofibrosis. The approval was based on its efficacy in reducing spleen size and improving disease-related burdensome symptoms. In the brief In the ...

hematologic malignancies

Pacritinib for Myelofibrosis: Effective in Patients With Thrombocytopenia

An emerging JAK inhibitor, pacritinib, appears not only effective in a broad population of patients with myelofibrosis but also among a subset with very low platelet counts, investigators from the global phase III PERSIST-1 trial reported at the 2015 ASCO Annual Meeting.1 “There is a huge unmet...

hematologic malignancies
issues in oncology

ASCO 2015: JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Findings from the PERSIST-1 study of patients with myelofibrosis show that the JAK inhibitor pacritinib is significantly more effective than best available therapy, which includes a range of off-label treatments, for easing the symptoms of myelofibrosis. At a landmark analysis at 24 weeks of...

Advertisement

Advertisement



Advertisement